Abstracts - PAGE Meeting (Population Approach Group Europe)

Abstracts (67)

II-01Teijo Saari

Significant changes in pharmacokinetics of sufentanil during target controlled infusion of sufentanil for cardiac anaesthesia.

Wednesday 15:10-16:40

II-02Muhammad Waqas Sadiq

Oxymorphone PKPD relationship and blood-brain barrier transport studied with microdialysis

Wednesday 15:10-16:40

II-03Mark Sale

Identification of optimal NONMEM models using a multi-objective genetic algorithm.

Wednesday 15:10-16:40

II-04

Mapping in vitro and in vivo derived CYP3A ontogeny function: A critical comparison between various ontogeny models

Wednesday 15:10-16:40

II-05Maria Luisa Sardu

Biomarker-driven Models of Tumour Growth Inhibition in preclinical animal studies

Wednesday 15:10-16:40

II-06Andre Schäftlein

Microdialysate-corrected mid-interval model versus microdialysate-based integral model – Population pharmacokinetics of levofloxacin in peripheral tissues

Wednesday 15:10-16:40

II-07Emilie Schindler

PKPD-Modeling of Standard Uptake Value (SUV) in Gastro-Intestinal Stromal Tumors (GIST) patients treated with sunitinib

Wednesday 15:10-16:40

II-08

Simultaneous population pharmacokinetic modelling of atazanavir and ritonavir in HIV-infected adults and assessment of different dose reduction strategies

Wednesday 15:10-16:40

II-09Rik Schoemaker

Modelling and simulation of spontaneously reported adverse events after administration of lacosamide

Wednesday 15:10-16:40

II-10Bernard Sebastien

Impact of delayed effect in Concentration-QT analyses.

Wednesday 15:10-16:40

II-11

Three case studies of pharmacokinetic model building using a multi-objective genetic algorithm

Wednesday 15:10-16:40

II-12Kwang-Hee Shin

Population Pharmacokinetics and Pharmacodynamics of Escitalopram in Healthy Volunteers

Wednesday 15:10-16:40

II-13Satoshi Shoji

Population Pharmacokinetics/Pharmacodynamics of Ampicillin/Sulbactam in Patients with Moderate or Severe Community-Acquired Pneumonia

Wednesday 15:10-16:40

II-14Hanna Silber Baumann

Population pharmacokinetics of cyclosporine A in cats

Wednesday 15:10-16:40

II-15Monica Simeoni

Estimation of Remifentanil Metabolic Ratio Using a Mixture Model

Wednesday 15:10-16:40

II-16Nicolas Simon

A joint PK/PD-PD model of levodopa in patients with Parkinson’s disease: Motor effect and Movement disorder

Wednesday 15:10-16:40

II-17

Development of a mechanistic based model for neonatal Fc receptor recycling to design human serum albumin mutants with extended half-lives

Wednesday 15:10-16:40

II-18Nelleke Snelder

Quantification of Antidepressant and Sedative Effect of Two NMDA Channel Blockers, AZD6765 and Ketamine, in an Animal Model of Depression Using Count Data

Wednesday 15:10-16:40

II-19Alexander Solms

Using Population PBPK Modelling to interpret Population PK results exemplified for Levofloxacin in Plasma and Interstitial Fluid

Wednesday 15:10-16:40

II-20

Development of a longitudinal model to describe the QT-time course in healthy volunteers given placebo and moxifloxacin

Wednesday 15:10-16:40

II-21Alexandre Sostelly

Dose and dose schedule optimization of anticancer drugs

Wednesday 15:10-16:40

II-22Alexander Staab

A Model-based Meta-analysis Comparison of the Effects of Linagliptin and Sitagliptin on HbA1c Levels in Patients with Type 2 Diabetes Mellitus

Wednesday 15:10-16:40

II-23David Stepensky

Inter-patient variability of local vs. systemic effects of TNF-α-neutralizing antibodies in rheumatoid arthritis

Wednesday 15:10-16:40

II-24Jasper Stevens

Nonlinear mixed effects evaluation of Hamilton Depression Rating Score following combination treatment of presynaptic- and postsynaptic glutamate receptor inhibitors in bipolar depression patients

Wednesday 15:10-16:40

II-25Elisabet Størset

Population pharmacokinetics of tacrolimus to aid individualized dosing in kidney transplant recipients

Wednesday 15:10-16:40

II-26

A Novel Pharmacodynamic Modeling Approach to Determine Long Term Disease Progression Rates in Japanese Type 2 Diabetes Patients: Pioglitazone vs. Conventional Therapy

Wednesday 15:10-16:40

II-28Herbert Struemper

Target-mediated clearance of ofatumumab: a tale of different disease states

Wednesday 15:10-16:40

II-29Elin Svensson

Linear approximation methods for fast evaluation of random effects models

Wednesday 15:10-16:40

II-30Stina Syvänen

P-glycoprotein alterations at the blood-brain barrier influences [11C]flumazenil brain concentrations but does not interfere with estimation of GABAA receptor density in a rodent model of epilepsy

Wednesday 15:10-16:40

II-31Takeshi Tajima

Mechanism-based assessment on the pharmacodynamics of neuromuscular relaxants and general consideration for receptor blockers

Wednesday 15:10-16:40

II-32Daniel Tatosian

Strategic comparator modeling and simulation to optimize dose selection for a dose-range finding study

Wednesday 15:10-16:40

II-33David Ternant

A model predicting expected infliximab serum concentrations using only dose and time since last infusion

Wednesday 15:10-16:40

II-34Nadia Terranova

Modelling of protozoa dynamics and drug effects in a murine model of malaria infection

Wednesday 15:10-16:40

II-35Hoai-Thu Thai

Residual-based bootstrap methods for estimating uncertainty of parameters in nonlinear mixed-effects models with heteroscedastic error

Wednesday 15:10-16:40

II-36Kirstin Thelen

Dynamically simulating the effect of food on gastric emptying using a detailed physiological model for gastrointestinal transit and absorption

Wednesday 15:10-16:40

II-37Mirjam Trame

Evaluating the Influence of Different Covariates on Enoxaparin Pharmacokinetics in Neonates, Infants and Children

Wednesday 15:10-16:40

II-38Kellie Turner

Adapting a Target-mediated Drug Disposition (TMDD) Model to Account for Delayed tmax Following IV Infusion of a Monoclonal Antibody

Wednesday 15:10-16:40

II-39Wanchana Ungphakorn

Development of Sparse Sampling Study of Oral Ciprofloxacin for Severely Malnourished Children

Wednesday 15:10-16:40

II-40Pyry Välitalo

Optimal design for a population pharmacokinetic study of oxycodone in preterm neonates, neonates and infants

Wednesday 15:10-16:40

II-41Marta Valle

Population pharmacokinetics of rupatadine in children 2-11 years of age with allergic rhinitis

Wednesday 15:10-16:40

II-42Sven van Dijkman

Characterisation of response and disease progression in paediatric epilepsy

Wednesday 15:10-16:40

II-43Coen van Hasselt

Model-based evaluation and optimization of cardiac monitoring protocols for adjuvant treatment of breast cancer with trastuzumab

Wednesday 15:10-16:40

II-44Charlotte van Kesteren

Predictive performance of a busulfan pharmacokinetic-model in children and young adults from five international transplant centers: a study of varying doses, underlying diseases, ethnicities, body weights, ages and body mass indices

Wednesday 15:10-16:40

II-45Eline van Maanen

A step-wise analysis of multiple biomarkers drives the development of a Semi-Mechanistic Comprehensive Model. Application to modulation of Amyloid-β.

Wednesday 15:10-16:40

II-46

Discrete distribution models for relapsing-remitting dynamics observed in Multiple Sclerosis

Wednesday 15:10-16:40

II-47Anders Viberg

Using modeling and simulation to evaluate placebo run-in for pain studies

Wednesday 15:10-16:40

II-48Marie Vigan

Evaluation of estimation methods for repeated time to event models: application to analysis of bone events during treatment of Gaucher Disease.

Wednesday 15:10-16:40

II-49

Population Analysis of wet-AMD Disease Progression and The Therapeutic Effect of Ranibizumab

Wednesday 15:10-16:40

II-50Sandra Visser

MModel-based meta analysis of -secretase inhibitor data; has A production inhibition been adequately tested as therapeutic approach in mild AD?

Wednesday 15:10-16:40

II-51Georgios Vlasakakis

Landscape on technical and conceptual requirements in Drug/Disease Modelling & Simulation

Wednesday 15:10-16:40

II-52Max von Kleist

PK-PD Modelling of the Reverse Transcriptase Inhibitor Tenofovir and Quantification of its Prophylactic Efficacy against HIV-1 Infection

Wednesday 15:10-16:40

II-53

Quantification of the Drug Effect and Exploration of Mechanism of Action of Two NMDA Channel Blockers, AZD6765 and Ketamine, using Mouse EEG Data

Wednesday 15:10-16:40

II-54

Population pharmacokinetics and pharmacodynamics of mavrilimumab in rheumatoid arthritis patients

Wednesday 15:10-16:40

II-55Chenguang Wang

Scaling morphine across the human life-span using a bodyweight-dependent allometric exponent model

Wednesday 15:10-16:40

II-56Sebastian Weber

Mixed effect modeling of neuronal cell differentiation kinetics from longitudinal phase-contrast imaging data

Wednesday 15:10-16:40

II-57Thomas Wendl

A whole-body physiologically-based pharmacokinetic Model for ketoconazole in different species ready to be used to predict dynamic drug-drug-interactions

Wednesday 15:10-16:40

II-58Shelby Wilson

The Enhancement of Tumor Vaccine Efficacy by Immunotherapy

Wednesday 15:10-16:40

II-59Gudrun Wuerthwein

Population Pharmacokinetics of caspofungin in a phase II dose escalation study

Wednesday 15:10-16:40

II-60Wenyuan Xiong

Pharmacokinetic interspecies extrapolation of a fully human mAb from animal to human

Wednesday 15:10-16:40

II-61Stefano Zamuner

PK-PD modelling of aOSM in RA patient study including exploration of carrier protein effect.

Wednesday 15:10-16:40

II-62Stefan Zeiser

Population PK Modeling of Dapivirine Released from Vaginal Rings

Wednesday 15:10-16:40

II-63Jianping Zhang

Population Analysis of Tumor Growth Inhibition and Progression-Free Survival Following Lapatinib Treatment in Patients with Advanced/Metastatic Breast Cancer

Wednesday 15:10-16:40

II-64Chao Zhang

Model-based evaluation of the pharmacokinetic differences between adults and children administered lopinavir and ritonavir in combination with rifampicin

Wednesday 15:10-16:40

II-65

Population pharmacokinetics and dosing optimization of vancomycin continuous infusion in neonates

Wednesday 15:10-16:40

II-66Kirill Zhudenkov

Application of the SBTOOLBOX2 in drug discovery and development

Wednesday 15:10-16:40

II-67BELA PATEL

Probability-Based Risk Assessment of QT Prolongation in Early Phase Drug Development

Wednesday 15:10-16:40

II-68Parviz Ghahramani

Population Pharmacokinetic Model for Cariprazine and its Major Metabolites in Patients with Acute Exacerbation of Schizophrenia

Wednesday 15:10-16:40